218 related articles for article (PubMed ID: 36494785)
1. Identification of CEACAM5 as a stemness-related inhibitory immune checkpoint in pancreatic cancer.
Shi H; Tsang Y; Yang Y
BMC Cancer; 2022 Dec; 22(1):1291. PubMed ID: 36494785
[TBL] [Abstract][Full Text] [Related]
2. Identification of inhibitory immune checkpoints and relevant regulatory pathways in breast cancer stem cells.
Shi H; Yang Y
Cancer Med; 2021 Jun; 10(11):3794-3807. PubMed ID: 33932112
[TBL] [Abstract][Full Text] [Related]
3. [Heterogeneity analysis of pancreatic cancer and identification of molecular subtypes of tumor cells based on CEACAM5, LGALS1 and CENPF gene expression].
Sun J; Lu P; Guan S; Liu S
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Sep; 43(9):1567-1576. PubMed ID: 37814871
[TBL] [Abstract][Full Text] [Related]
4. Identification of ONECUT3 as a stemness-related transcription factor regulating NK cell-mediated immune evasion in pancreatic cancer.
Shi H; Tsang Y; Yang Y; Chin HL
Sci Rep; 2023 Oct; 13(1):18133. PubMed ID: 37875589
[TBL] [Abstract][Full Text] [Related]
5. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
[TBL] [Abstract][Full Text] [Related]
6. Prognostic clinical phenotypes associated with tumor stemness in the immune microenvironment of T-cell exhaustion for hepatocellular carcinoma.
Zhang G
Discov Oncol; 2023 Nov; 14(1):203. PubMed ID: 37957420
[TBL] [Abstract][Full Text] [Related]
7. Cancer Stemness Associated With Prognosis and the Efficacy of Immunotherapy in Adrenocortical Carcinoma.
Shi X; Liu Y; Cheng S; Hu H; Zhang J; Wei M; Zhao L; Xin S
Front Oncol; 2021; 11():651622. PubMed ID: 34367952
[TBL] [Abstract][Full Text] [Related]
8. Characterization of stemness features and construction of a stemness subtype classifier to predict survival and treatment responses in lung squamous cell carcinoma.
Lai J; Lin X; Zheng H; Xie B; Fu D
BMC Cancer; 2023 Jun; 23(1):525. PubMed ID: 37291533
[TBL] [Abstract][Full Text] [Related]
9. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
10. Immunological Value of Prognostic Signature Based on Cancer Stem Cell Characteristics in Hepatocellular Carcinoma.
Xu Q; Xu H; Chen S; Huang W
Front Cell Dev Biol; 2021; 9():710207. PubMed ID: 34409040
[No Abstract] [Full Text] [Related]
11. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
12. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
13. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.
Zhang Z; Wang ZX; Chen YX; Wu HX; Yin L; Zhao Q; Luo HY; Zeng ZL; Qiu MZ; Xu RH
Genome Med; 2022 Apr; 14(1):45. PubMed ID: 35488273
[TBL] [Abstract][Full Text] [Related]
14. Stemness analysis in hepatocellular carcinoma identifies an extracellular matrix gene-related signature associated with prognosis and therapy response.
Chen L; Zhang D; Zheng S; Li X; Gao P
Front Genet; 2022; 13():959834. PubMed ID: 36110210
[No Abstract] [Full Text] [Related]
15. Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma.
Tian X; Zheng J; Mou W; Lu G; Chen S; Du J; Zheng Y; Chen S; Shen B; Li J; Wang N
Front Pharmacol; 2022; 13():939542. PubMed ID: 35935823
[No Abstract] [Full Text] [Related]
16. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
[TBL] [Abstract][Full Text] [Related]
17. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
18. The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway.
Fantini M; David JM; Annunziata CM; Morelli MP; Arlen PM; Tsang KY
Cancer Biother Radiopharm; 2020 Apr; 35(3):190-198. PubMed ID: 31928422
[No Abstract] [Full Text] [Related]
19. Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.
Seckinger A; Majocchi S; Moine V; Nouveau L; Ngoc H; Daubeuf B; Ravn U; Pleche N; Calloud S; Broyer L; Cons L; Lesnier A; Chatel L; Papaioannou A; Salgado-Pires S; Krämer S; Gockel I; Lordick F; Masternak K; Poitevin Y; Magistrelli G; Malinge P; Shang L; Kallendrusch S; Strein K; Hose D
J Hematol Oncol; 2023 Dec; 16(1):117. PubMed ID: 38087365
[TBL] [Abstract][Full Text] [Related]
20. Tumor stemness and immune infiltration synergistically predict response of radiotherapy or immunotherapy and relapse in lung adenocarcinoma.
Shi H; Han L; Zhao J; Wang K; Xu M; Shi J; Dong Z
Cancer Med; 2021 Dec; 10(24):8944-8960. PubMed ID: 34741449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
